Updates in the Treatment of Secondary Acute Myeloid Leukemia

News
Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

This video reviews the biology of secondary acute myeloid leukemia and highlights some of the latest findings in the treatment of this disease.

In this video, Bruno C. Medeiros, MD, of the Stanford School of Medicine in California, reviews the biology of secondary acute myeloid leukemia and highlights some of the latest findings in the treatment of this disease, including the promising novel agent CPX-351.

Medeiros spoke on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Recent Videos
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Related Content
Data from a phase 1 trial may support additional clinical studies of CT0596 in relapsed/refractory multiple myeloma.

Novel Anti-BCMA Agent Shows Preliminary Responses in R/R Multiple Myeloma

Russ Conroy
December 20th 2025
Article

Data from a phase 1 trial may support additional clinical studies of CT0596 in relapsed/refractory multiple myeloma.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Nuvisertib combined with momelotinib achieved a spleen volume reduction of 25% at week 24 and any given time in 50% of patients with relapsed/refractory myelofibrosis.

Nuvisertib Combo Improves Safety in JAK-Pretreated R/R Myelofibrosis

Ryan Scott
December 12th 2025
Article

Nuvisertib combined with momelotinib achieved a spleen volume reduction of 25% at week 24 and any given time in 50% of patients with relapsed/refractory myelofibrosis.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Across all dose levels of axatilimab, the 46-month OS rate was the 74.1% among patients with previously treated chronic graft-vs-host disease.

Axatilimab Confers Promising Early Efficacy/Tolerability in Chronic GVHD

Jonah Feldman
December 11th 2025
Article

Across all dose levels of axatilimab, the 46-month OS rate was the 74.1% among patients with previously treated chronic graft-vs-host disease.

Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma

Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma

Ariana Pelosci
December 11th 2025
Article

The FDA has given a PDUFA date of April 8, 2026, to the nivolumab/AVD regimen for stage III or IV classical Hodgkin lymphoma.